Page last updated: 2024-11-12
ci 959
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CI 959: antiallergy compound; inhibits thromboxanes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 13961743 |
CHEMBL ID | 3183386 |
MeSH ID | M0170923 |
Synonyms (16)
Synonym |
---|
ci-959 |
ci 159 |
ci 959 |
benzo(b)thiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-n-1h-tetrazol-5-yl-, monosodium salt |
tox21_300435 |
cas-104795-68-8 |
dtxcid6027268 |
NCGC00254320-01 |
dtxsid8047268 , |
104795-68-8 |
unii-1a8130p4iy |
1a8130p4iy , |
benzo(b)thiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-n-2h-tetrazol-5-yl-, sodium salt (1:1) |
CHEMBL3183386 |
Q27252149 |
sodium;5-methoxy-3-propan-2-yloxy-n-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)-1-benzothiophene-2-carboxamide |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" CI-959 was locally toxic to nasal cavity respiratory and olfactory epithelia in rats and respiratory epithelium in dogs." | ( Nasal toxicity of CI-959, a novel anti-inflammatory drug, in Wistar rats and Beagle dogs. Courtney, CL; Walsh, KM, ) | 0.13 |
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" Maximum plasma drug concentrations (Cmax) were significantly higher when CI-959 was given by bolus intravenous injection, suggesting that cardiac effects were dependent on high Cmax concentrations." | ( Cardiac hypertrophy in rats after intravenous administration of CI-959, a novel antiinflammatory compound: morphologic features and pharmacokinetic and pharmacodynamic mechanisms. Henry, SP; Knowlton, P; Loewen, G; Low, JE; Mertz, TE; Metz, AL; Olszewski, BJ; Robertson, DG; Schroeder, RL; Sommers, CS, 1995) | 0.29 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Salivation at dosing was seen in both species." | ( Nasal toxicity of CI-959, a novel anti-inflammatory drug, in Wistar rats and Beagle dogs. Courtney, CL; Walsh, KM, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (23)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 10.3737 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 3.8757 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
SMAD family member 3 | Homo sapiens (human) | Potency | 3.8757 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 7.5536 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 25.8381 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743053; AID743063 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 28.8724 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 54.2611 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 54.7461 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 52.7481 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 24.4542 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 25.5051 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 54.2611 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 27.9721 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 29.1002 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 15.6364 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 15.7388 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223; AID743241 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 24.2376 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 10.9233 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 6.4596 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 28.8541 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 30.5133 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 13.6298 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 30.5133 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (20)
Research
Studies (19)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (5.26) | 18.7374 |
1990's | 13 (68.42) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 5 (26.32) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.46
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.46) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (10.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (90.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |